Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06958536 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
A Phase 2 study of Crohn's Disease, sponsored by Sanofi.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
- 20
- Study locations
NCT06958536 is a Phase 2 study of Crohn's Disease that is actively recruiting participants, run by Sanofi. The registered enrollment target is 99 participants, below the 2,414-participant average among 104 other Crohn's Disease trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT06958536, a Phase 2 study of Crohn's Disease, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Crohn's disease. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SAR442970
Study Locations (20)
Florida
- Investigational Site Number: 8400017 - Kissimmee
- Investigational Site Number: 8400015 - Lighthouse PT
- Investigational Site Number 84000028 - Miami
- Investigational Site Number: 8400012 - Miami
- Investigational Site Number: 8400007 - Orlando
- Investigational Site Number: 8400011 - Palmetto Bay
California
- Investigational Site Number: 8400005 - Escondido
- Investigational Site Number: 8400001 - Lancaster
Arizona
- Investigational Site Number: 84000024 - Tucson
Georgia
- Investigational Site Number: 8400019 - Marietta
Iowa
- Investigational Site Number: 8400025 - Iowa City
Kansas
- Investigational Site Number: 8400006 - Kansas City
Massachusetts
- Investigational Site Number: 8400022 - Boston
Michigan
- Investigational Site Number: 8400008 - Wyoming
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2025-06-03 |
| Est. Completion | 2029-10-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06958536
The ClinicalTrials.gov registry entry for NCT06958536 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,414-participant average among 104 other Crohn's Disease trials with a reported enrollment target (96% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06958536 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06958536 about?
NCT06958536 is a clinical study titled "A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease". This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Crohn's disease. The total study duration is up ...
What is the current status of trial NCT06958536?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2025-06-03. Estimated completion is 2029-10-17.
What conditions does trial NCT06958536 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT06958536?
The interventions under investigation include: Placebo (DRUG), SAR442970 (DRUG).
Who is sponsoring clinical trial NCT06958536?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06958536 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 2
-
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 2
-
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
RECRUITING · Phase 2
-
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
RECRUITING · Phase 2
-
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.